In our war against the opioid epidemic, could 'weed' be a winner?


Journal

Expert review of pharmacoeconomics & outcomes research
ISSN: 1744-8379
Titre abrégé: Expert Rev Pharmacoecon Outcomes Res
Pays: England
ID NLM: 101132257

Informations de publication

Date de publication:
Oct 2020
Historique:
pubmed: 18 8 2020
medline: 7 2 2021
entrez: 18 8 2020
Statut: ppublish

Résumé

The opioid epidemic has resulted in the deaths of millions of Americans and was declared a public health emergency in 2017. In response, many states have enacted policies and analyzed various interventions for harm reduction and overdose prevention, which have embraced limited success. With more states legalizing medical marijuana, another intervention of interest in pain management, much research has since focused on the potential for medical marijuana laws (MMLs) to curb the opioid epidemic. Nonetheless, marijuana legalization and its use for medical purposes has been a polarizing debate from ethical, social, and clinical perspectives. We examine evidence on the merits of medical marijuana to address its potential as a diversion from prescription painkillers. Additionally, we review the impact of MMLs on opioid-related outcomes. Furthermore, we provide multi-layered recommendations for future directions in the evaluation of medical marijuana and MMLs as potential mitigators of the opioid epidemic. Despite limited and mixed evidence of efficacy, medical marijuana may still play an important role in addressing the opioid epidemic in the United States. Furthermore, we believe coordinated responses among the federal government, states, researchers, and patients are crucial in producing more robust evaluations of medical marijuana and MMLs.

Identifiants

pubmed: 32799573
doi: 10.1080/14737167.2020.1807944
doi:

Substances chimiques

Medical Marijuana 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

423-429

Auteurs

Delaney D Ding (DD)

Clinical Research Coordinator, Medical Practice Evaluation Center, Massachusetts General Hospital , Boston, MA, USA.

Rajesh Balkrishnan (R)

University of Virginia School of Medicine, Clinical Professor, University of Virginia School of Nursing , Charlottesville, VA, USA.

Vakaramoko Diaby (V)

Department of Pharmaceutical Outcomes and Policy (POP), College of Pharmacy, University of Florida , Gainesville, FL, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH